Logo

Medis Pharmaceuticals Reports Clinical Trial Results of Enoxa for the Prevention of Postoperative Subclinical Thrombosis

Share this
Medis Pharmaceuticals

Medis Pharmaceuticals Reports Clinical Trial Results of Enoxa for the Prevention of Postoperative Subclinical Thrombosis

Shots: 

  • The clinical trial evaluated the equivalence of Enoxa to Sanofi’s Lovenox in patients (n= 74 vs 71) with digestive cancers to prevent postoperative subclinical thrombosis across Tunisia  
  • The 1EP of the study was asymptomatic thromboembolic events assessed by Doppler ultrasound & 2EPs include thrombotic events, heparin-induced thrombocytopenia, bleeding events, and deaths  
  • As per the results, out of the evaluable patients, 4.1% vs 5.6% depicted a subclinical venous thrombosis whereas 6.9% vs 8.6% of patients showed combined clinical & subclinical events. Moreover, in terms of other 2EPs, there were no significant differences between the groups & death occurred in 12.6% vs 7.4% of patients  

Ref: Center For Biosimilar | Image:  Anthos Therapeutics

Related News:- Anthos’ Abelacimab Receives the US FDA’s Fast Track Designation for the Treatment of Thrombosis Associated with Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions